- Drugs
- Wednesday, 15 Jul 2020
AstraZeneca ties up with IQVIA to speed up studies of COVID-19 vaccine candidate
Life sciences company IQVIA Holdings Inc said on Tuesday it would collaborate with AstraZeneca Plc to speed up clinical studies of the British drugmaker’s potential COVID-19 vaccine in the United States.
The collaboration is part of the U.S. government’s Operation Warp Speed to accelerate the development of COVID-19 vaccines and treatments.
AstraZeneca is among the drugmakers farthest along in the race to develop a safe and effective vaccine for COVID-19, the respiratory disease caused by the new coronavirus. The British drugmaker has received U.S. funding of more than $1 billion to secure access to dosages.
The agreement includes an expansive study of trial participants and will use IQVIA’s virtual trial solutions that would make parts of the study remote.
Clinical trial service providers like IQVIA have seen a boost in demand for their offerings in virtual care - an area that has been slow to catch on - as the pandemic forces people to self-isolate and stay at home.
Related Industry Updates
MigVax appoints Eyal Desheh, former Teva, Check Point executive, as chairman
Jun 09, 2020
Australia & South Korea Diabetic Foot Ulcer Market is expected to reach US$ 313.53 billion by 2030
Sep 20, 2023
Stomach Cancer Market is expected to reach US$ 10,751.42 million by 2030
Dec 28, 2023
Drugmaker Sanofi to raise over $11 billion by selling its U.S. partner Regeneron shares
May 27, 2020
FDA Clears ACCRUFeR® (ferric maltol) for Iron Deficiency
Feb 18, 2026
Aquatic Veterinary Market is expected to reach US$ 1,934.33 million by 2030
Feb 19, 2024
HempMeds®, Subsidiary of Medical Marijuana, Inc., Becomes One of the First Companies to Join Recently Launched Leafly Market
Dec 20, 2019
Follow us on
